Biohaven Ltd. (BHVN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in New Haven, CT, United States. The current CEO is Vladimir Coric.
BHVN has IPO date of 2022-09-23, 256 full-time employees, listed on the NYSE, a market capitalization of $1.11B.
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
